Showing 5551-5560 of 5771 results for "".
- SynergEyes and Brien Holden Vision Institute Join Forces for Specialty Contact Lens Developmenthttps://modernod.com/news/synergeyes-and-brien-holden-vision-institute-join-forces-for-specialty-contact-lens-development/2480098/SynergEyes announced a new partnership with the Brien Holden Vision Institute, a translational vision correction center that delivers advanced, customized vision correction for myopes and presbyopes. The exclusive worldwide licensing agreement will enable the manufacturing of design technologies
- CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa Drug Formulationshttps://modernod.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally proce
- Quantel Medical Creates a New Subsidiary in Polandhttps://modernod.com/news/quantel-medical-creates-a-new-subsidiary-in-poland/2480102/Quantel Medical has announced the opening of its new Polish subsidiary: Quantel Medical Polska. The new location will commercialize the complete range of ultrasound, laser, and dry eye diagnostics products. Quantel Me
- Optovue Receives FDA Clearance for AngioAnalytics – the First OCT Angiography Metrics Technologyhttps://modernod.com/news/optovue-receives-fda-clearance-for-angioanalytics-the-first-oct-angiography-metrics-technology/2480103/Optovue announced FDA 510(k) clearance of AngioAnalytics, the first optical coherence tomography angiography (OCTA) blood vessel measurement technology to help clinicians manage diseases that cause progressive blindness. The company also received clearance for its three-dimensional projection art
- Wichita Optometry Expands Services With the Purchase of Two Practiceshttps://modernod.com/news/wichita-optometry-expands-services-with-the-purchase-of-two-practices/2480105/Wichita Optometry has announce the expansion of its service area with the purchase of two additional optometry practices: Mulvane Vision Care and Wichita Vision Care. Mulvane Vision Care is located at 415 S.E. Louis Blvd. in Mulvane, Kansas and Wichita Vision Care is located at 12111 W. Maple St.
- Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Deliveryhttps://modernod.com/news/eyenovia-receives-notices-of-allowance-from-uspto-on-two-additional-patent-applications-for-ophthalmic-drug-delivery/2480109/Eyenovia announced it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for two additional patent applications. The allowed patents provide fundamental coverage on physiologic microdroplet ejection diameters and velocities, which enable gentle delivery of ophthal
- Orasis Pharmaceuticals Closes $13 Million Series B Financinghttps://modernod.com/news/orasis-pharmaceuticals-closes-13-million-series-b-financing/2480119/Privately-held Orasis Pharmaceuticals announced the closing of a $13 million Series B financing to be used to advance Orasis’s lead product candidate, CSF-1, an eye drop being developed for the treatment of presbyopia symptoms, through completion of its phase 2b clinical trial. The proceeds will
- Tobii and Lumus Bring Eye Tracking Technology to Augmented Reality Eyewearhttps://modernod.com/news/tobii-and-lumus-bring-eye-tracking-technology-to-augmented-reality-eyewear/2480121/At the Augmented World Expo (AWE) this week, Tobii announced that it is working with Lumus, a provider of transparent displays for augmented reality (AR), to incorporate eye tracking technology as part of the Lumus DK50 AR development kit.
- Bausch + Lomb Enrolls First Patient in Envista MX60EF Trifocal IOL Clinical Trialhttps://modernod.com/news/bausch-lomb-enrolls-first-patient-in-envista-mx60ef-trifocal-iol-clinical-trial/2480122/Bausch + Lomb announced that it has enrolled the first patient in a clinical trial studying the efficacy and safety of an investigational trifocal IOL, the enVista MX60EF. The study is intended to support a premarket approval (PMA) application filing with the FDA. The enVista MX60EF trifoc
- NTC to Strengthen Its Ophthalmology Portfolio Through the Acquisition of Ocular Antibiotic Productshttps://modernod.com/news/ntc-to-strengthen-its-ophthalmology-portfolio-through-the-acquisition-of-ocular-antibiotic-products/2480127/The Italian pharmaceutical company NTC announced the acquisition of some Novartis ocular antibiotic products, including broad spectrum antibiotic therapies to treat eye diseases. Countries covered under the agreement include Spain, Portug